Platinum Level
Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Our Immunology disease research combines our proven ability to address unmet medical needs with pioneering patient-centered approaches to accelerate the discovery of breakthrough therapies.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
Are your media TRULY human and animal component-free, and clinically ready? Ours are.
Switch to CELLnTEC’s market-leading precision skin cell culture system!
CELLnTEC is a pioneering provider of chemically defined, animal and human component-free precision media. Around the world, we empower scientists to conduct tissue engineering and to create sophisticated in-vitro cell models in applications ranging from 2D/3D cell culture to organoids, lab-on-a-chip or 3D bioprinting, across a range of skin tissue types, iPSC and ESC.
Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs. We are exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions, including atopic dermatitis, vitiligo and hidradenitis suppurativa.
Novartis is reimagining medicine to improve people’s lives. We use innovative science and digital technologies to create transformative treatments. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our medicines. About 109,000 people of more than 145 nationalities work at Novartis.
Tergus Pharma is an end-to-end service provider for topical pharmaceutical products supporting early phase research and formulation, drug development, testing, and both clinical and commercial manufacturing at our new 100,000 sq. ft. state-of-the-art facility in Durham, North Carolina.
Tergus is the industry leader for topical/skin semi-solids and liquids as well as other non-skin semi-solids/liquids for vaginal, rectal, and optic/ophthalmic routes of administration where we recognize the value of our stellar industry reputation for delivering quality results to clients. With industry-recognized leadership and expertise in method development, such as IVRT/IVPT for topical pharmaceuticals, Tergus also provides clients with peace of mind and helps them to de-risk their product development. Exclusively focused on topical development and manufacturing, Tergus brings the scientific expertise that helps our clients achieve the right balance of scientific knowhow, speed of results, and quality in product service, warranting our company motto, “Think Topicals, Think Tergus.”
Gold Level
Respiratory & Immunology is one of AstraZeneca’s three therapy areas and is a key growth driver for the Company.
AstraZeneca is an established leader in respiratory care with a 50-year heritage. The Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death. The Company’s early respiratory research is focused on emerging science involving immune mechanisms, lung damage and abnormal cell-repair processes in disease and neuronal dysfunction.
With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas. The Company’s growing presence in immunology is focused on five mid- to late-stage franchises with multi-disease potential, in areas including rheumatology (including systemic lupus erythematosus), dermatology, gastroenterology, and systemic eosinophilic-driven diseases. AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.
Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions.
From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed (https://castletestinfo.com).
DecisionDx®-Melanoma predicts risk of recurrence or metastasis that can inform decisions regarding sentinel lymph node biopsy and the intensity of follow-up, surveillance imaging, referral, and adjuvant therapy for patients with invasive cutaneous melanoma. The test uses tumor biology to provide an individual risk of melanoma recurrence beyond traditional factors such as AJCC staging criteria and integrates the 31-GEP score with clinicopathologic factors (i31-GEP) to determine the likelihood of sentinel lymph node positivity. DecisionDx-Melanoma is supported by consistent evidence in 30 publications including two meta-analyses showing Level 1A evidence classification.
DecisionDx® DiffDx-Melanoma is a new gene expression profile test designed to reduce diagnostic uncertainty by providing a highly accurate and objective evaluation. DiffDx-Melanoma adds diagnostic clarity leading to a more confident diagnosis and a clearer treatment path for patients.
DecisionDx®-SCC predicts metastatic risk for patients with cutaneous squamous cell carcinoma who have one or more risk factors. The test complements factors commonly used for risk assessment in SCC. The incorporation of DecisionDx-SCC results with traditional risk factors provides additional risk prediction to better inform choices about treatment and follow-up care.
DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. The test is standard of care in a majority of ocular oncology practices.
Castle Biosciences has active research and development programs for tests in other dermatologic diseases with high clinical need. The company is based in Friendswood, Texas with laboratory operations in Phoenix, Arizona.
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform.
DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments.
Genemarkers is a precision health company with a foundation in contract research that empowers personal care companies to create safe, effective products while establishing brand loyalty for their products, active ingredients and raw materials through genomics.
Our laboratory is located in Kalamazoo, MI and we have been serving the personal care industry for over 10 years, we specialize in:
• Genomic biomarker analysis
• microRNA profiling
• Genotyping
• Early safety screening
Genemarker’s also has the ability to run various ELISAs and incorporate additional challenger methods (such as pollutants, UV, blue light {coming soon!}) to study designs if our sponsor chooses.
The study sponsor can choose to test on a variety of cellular models such as 2d monolayer cells, in-vitro, and ex-vivo. We have the capacity to culture cell lines in-house and source a variety of specialty ex vivo or in vitro models such as psoriatic induced or wounded tissues.
These types of assays offer our sponsors the opportunity to validate their products efficacy, understand synergistic effects of ingredients, and even determine new uses.
Companies choose to partner with Genemarkers because of our high-touch consultative and hands-on approach from study design to the personalized, easy to understand final report of data.
If you are interested in learning more about how genomic profiling will enhance your research and development process then reach out to us!
Regeneron is a leading biotechnology company that invents medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation around the globe.
Partners
FSR is actively working with the world leaders in sarcoidosis, investing in innovative, patient-centered research efforts and providing educational resources, support, and opportunities to accelerate research to patients worldwide.
Our Mission
The Foundation for Sarcoidosis Research is the nation’s leading nonprofit organization dedicated to finding a cure for this disease and to improving care for sarcoidosis patients. Since its establishment in 2000, FSR has fostered over $5 million in sarcoidosis-specific research efforts and has worked diligently to provide resources to thousands.
Our Goals
Finding a Cure
FSR provides funding and collaborations for research and initiatives which focus on the understanding of sarcoidosis, addresses the causes of the disease, counters the suffering of patients, and advances the potential for a cure. Through collaborations and partnerships with the pharmaceutical industry, biotech companies, medical institutes and professionals, academic institutes, researchers, and patients from across the globe, FSR is producing game-changing initiatives toward a cure. In the years ahead, the Foundation looks forward to increasing our investment to find innovative breakthroughs which will provide treatments, therapies and a cure for the disease.
Educating and Resourcing Patients and the Public
Patients can be KEY elements in progress toward better treatments and a cure! FSR educates and connects patients with opportunities to become involved by becoming knowledgeable about sarcoidosis research. This includes participating in clinical trials, tissue donation programs, patient registries and shared data for research. FSR also offers annual conferences, webinars and comprehensive educational materials for people across the globe living with sarcoidosis, and connects patients to each other for support and enabling a larger impact. More than 46,000 members from all 50 states and nearly 80 countries have joined our free Stop Sarcoidosis Online Support Community. Thousands more are helped through in-person support groups under the umbrella of FSR. We are committed to informing the public about the disease and the dire need for increased funding, as this will in turn advance research and an understanding of the disease.
FSR believes in the power of many to join forces for true game-changing results in sarcoidosis research. The quality of life – and life itself – of thousands of patients depends on a true collaborative process. Only then will we see true results.
The International Alliance of Dermatology Patient Organizations (IADPO) – also known as GlobalSkin – is a unique global alliance, committed to improving the lives of patients worldwide.
We nurture relationships with members, partners and all involved in healthcare – building dialogue with decision-makers around the globe to promote patient-centric healthcare. GlobalSkin’s work is founded on three pillars: research, advocacy and support.
Founded in 1988, the National Eczema Association (NEA) is a 501(c)(3) nonprofit and the largest patient advocacy organization serving the over 31 million Americans who live with eczema and those who care for them. NEA provides programs and resources to elevate the diverse lived experience of eczema, and help patients and caregivers understand their disease, actively engage in their care, find strength in one another – and improve their lives.
Additionally, NEA advances critical eczema research and partners with key stakeholders to ensure the patient voice is represented and valued in education, care and treatment decision making. The eczema community is at an exciting juncture, with increased recognition of the seriousness and burden of eczema and a surge in scientific interest and development of new treatments. Bolstered by NEA’s strategic plan, Blueprint 2025, we are driving toward the ultimate vision: a world without eczema.
The National Psoriasis Foundation (NPF) is a nonprofit organization with a mission to drive efforts to cure psoriatic disease and improve the lives of those affected.
Founded in 1967 from classified ad in a Portland, Oregon, newspaper, NPF is the leading national nonprofit organization supporting research on psoriasis and psoriatic arthritis and advocating for the needs of the psoriatic disease community for the more than 8 million Americans living with psoriasis and psoriatic arthritis. NPF is headquartered in Portland, Oregon, with community divisions and volunteers across the U.S.
The current five-year strategic plan, which runs until June 30, 2024, is driven by overarching goals in research, health, and constituent resources:
Research – Lead collaborative, transformational research in psoriatic disease
Health – Increase the lifespan and health of individuals living with psoriatic disease
Resources – Secure the human, technological and financial resources necessary to achieve our mission-related goals
The National Psoriasis Foundation offers support to patients, researchers, medical providers, and family members through offering research funding, continuing medical education for providers, patient advocacy, and a dedicated team of patient navigators providing support and educational materials to interested constituents.
Pachyonychia Congenita Project (PC Project)
PC Project connects patients, researchers, medical professionals, and industry partners in a united and global effort to help those who suffer from the painful and debilitating effects of Pachyonychia Congenita (PC), a rare genetic skin disease.
The International Pachyonychia Congenita Research Registry (IPCRR) gathers data from patients through an online registry and provides free genetic testing to those who join. Patients in the registry are offered individualized support and are notified of studies for PC treatments, advances in research, and activities such as online forums and patient support meetings.
PC Project sponsors the International PC Consortium (IPCC) which facilitates collaboration among scientists, physicians, and other professionals interested in advancing research and translational therapeutics for PC. De-identified data from the registry is freely shared and available for research. PC Project invites all interested physicians, scientists and industry partners to join the IPCC, a special group, founded and fueled by love for these patients with severe unmet needs.
Please partner with us to help achieve our vision, which is a day when those who suffer from PC will live without excruciating pain, isolation, and embarrassment.
We look forward to welcoming you to Portland for the 2022 Annual Meeting! May 18-21, 2022 at the Oregon Convention Center!